Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cyproterone Acetate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Cyproterone Acetate. Displaying page 1 of 1.
    EudraCT Number: 2005-002409-21 Sponsor Protocol Number: 358 Start Date*: 2005-11-09
    Sponsor Name:Population Council - Center for Biomedical Research
    Full Title: A dose-finding randomized clinical trial to evaluate the differential impact of four progestins for their use as male contraceptives in healthy men.
    Medical condition: This clinical trial tests several products for their future usefulness for male contraception.
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000502-19 Sponsor Protocol Number: PSY-NIL-0002 Start Date*: 2016-06-21
    Sponsor Name:Medical University of Vienna, Department of Psychiatry and Psychotherapy
    Full Title: Effects of sex steroid hormones on serotonin synthesis and degradation measured with PET
    Medical condition: Gender Dysphoria (Female-to-male transsexuals and male-to-female transsexuals)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004545-15 Sponsor Protocol Number: MLAM 2007/01 Start Date*: 2008-06-10
    Sponsor Name:University Medical Center Utrecht
    Full Title: The Split Dose Study: Split dose Rhenium-188-HEDP regimen in hormone refractory prostate cancer patients with bone metastases; a phase I toxicity study and phase II efficacy study.
    Medical condition: Hormone refractory prostate cancer with painful bone metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001030-33 Sponsor Protocol Number: MRCPR09 Start Date*: 2005-11-23
    Sponsor Name:University College London
    Full Title: PATCH Prostate Adenocarcinoma: TransCutaneous Hormones A randomised-controlled trial of transcutaneous oestrogen patches versus LHRH agonists in prostate cancer.
    Medical condition: Newly diagnosed or relapsing patients with locally advanced or metastatic prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-004564-32 Sponsor Protocol Number: NG 05 / 09 Start Date*: 2007-03-06
    Sponsor Name:University Medical center Utrecht
    Full Title: The Prostate CARE Study: Capecitabine (Xeloda®) combined with Rhenium-188-HEDP in hormone refractory prostate cancer patients with bone metastases; a Capecitabine phase I dose escalation study and...
    Medical condition: Hormone refractory prostate cancer with painful bone metastases
    Disease: Version SOC Term Classification Code Term Level
    8.1 10036909 Prostate cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001440-99 Sponsor Protocol Number: ANB019-208 Start Date*: 2021-08-25
    Sponsor Name:AnaptysBio Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects with Hidradenitis Suppurativa
    Medical condition: Hidradenitis Suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-018109-29 Sponsor Protocol Number: MINALO3004 Start Date*: 2010-07-05
    Sponsor Name:Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.
    Full Title: A PHASE 3 MULTI-CENTER PARALLEL DESIGN CLINICAL TRIAL TO COMPARE THE EFFICACY AND SAFETY OF 5% MINOXIDIL FOAM VS. 2% MINOXIDIL SOLUTION IN FEMALES FOR THE TREATMENT OF FEMALE PATTERN HAIR LOSS (AND...
    Medical condition: FEMALE PATTERN HAIR LOSS (ANDROGENETIC ALOPECIA)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10068168 Androgenetic alopecia LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-019881-96 Sponsor Protocol Number: MINALO3005 Start Date*: 2010-11-19
    Sponsor Name:Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.
    Full Title: A PHASE 3 MULTI-CENTER PARALLEL DESIGN CLINICAL TRIAL TO COMPARE THE EFFICACY AND SAFETY OF 5% MINOXIDIL FOAM VS. VEHICLE IN FEMALES FOR THE TREATMENT OF FEMALE PATTERN HAIR LOSS (ANDROGENETIC ALOP...
    Medical condition: FEMALE PATTERN HAIR LOSS (ANDROGENETIC ALOPECIA)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10040785 - Skin and subcutaneous tissue disorders 10068168 Androgenetic alopecia PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-012226-37 Sponsor Protocol Number: PIOMET-55 Start Date*: 2010-01-15
    Sponsor Name:HOSPITAL SANT JOAN DE DÉU
    Full Title: Ensayo clínico piloto de tratamiento con Pioglitazona+Flutamida+Metformina a Dosis Bajas versus Etinil-Estradiol + Acetato de Ciproterona como control, en Adolescentes con Hiperandrogenismo Ovárico...
    Medical condition: Hiperandrogenismo ovárico asociado a hiperinsulinismo.
    Disease:
    Population Age: Adolescents, Under 18 Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003585-34 Sponsor Protocol Number: METRO Start Date*: 2006-08-28
    Sponsor Name:
    Full Title: WEEKLY DOCETAXEL COMBINED WITH DAILY ORAL LOW DOSES OF PREDNISONE AND CYCLOPHOSPHAMIDE IN HORMONE-REFRACTORY PROSTATE CARCINOMA A PHASE I/II STUDY
    Medical condition: hormone refractory prostate carcinoma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10036908 HLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000248-23 Sponsor Protocol Number: C3441052 Start Date*: 2021-10-22
    Sponsor Name:Pfizer Inc.
    Full Title: TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
    Medical condition: Metastatic Castration-sensitive Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Ongoing) DE (Ongoing) NO (Ongoing) SK (Ongoing) FI (Ongoing) BE (Ongoing) NL (Ongoing) ES (Ongoing) BG (Ongoing) HU (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-006050-51 Sponsor Protocol Number: RD.06.SPR.202395 Start Date*: 2021-08-03
    Sponsor Name:Galderma S.A.
    Full Title: Evaluation of the risk of atrophic acne scar formation during treatment of acne vulgaris subjects with trifarotene 50 µg/g cream versus vehicle cream over 24 weeks
    Medical condition: acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10000519 Acne vulgaris LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-003494-22 Sponsor Protocol Number: ANB019-207 Start Date*: 2021-02-24
    Sponsor Name:AnaptysBio Inc.
    Full Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ANB019 in the Treatment of Acneiform Rash in Subjects with Cancer Receiving EGFRi or MEKi Therapy
    Medical condition: Acneiform Rash
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004858 10037847 Rash acneiform LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) CZ (Prematurely Ended) LV (Prematurely Ended) BG (Prematurely Ended) HU (Completed)
    Trial results: View results
    EudraCT Number: 2004-000193-31 Sponsor Protocol Number: PR08 Start Date*: 2004-10-04
    Sponsor Name: University College London
    Full Title: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy
    Medical condition: Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001186 Adenocarcinoma of prostate LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001198 Adenocarcinoma of the prostate metastatic LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001199 Adenocarcinoma of the prostate recurrent LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007113 Cancer of prostate LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007453 Carcinoma of the prostate metastatic LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007454 Carcinoma of the prostate recurrent LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007462 Carcinoma prostate LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036921 Prostate carcinoma LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 08:52:35 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA